Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2025 value amounting to $9.5 million.

  • Orchestra BioMed Holdings' Change in Acquisitions & Divestments fell 1042.12% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year decrease of 4447.65%. This contributed to the annual value of $86.6 million for FY2024, which is 4330.52% down from last year.
  • According to the latest figures from Q3 2025, Orchestra BioMed Holdings' Change in Acquisitions & Divestments is $9.5 million, which was down 1042.12% from $16.4 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Change in Acquisitions & Divestments high stood at $51.5 million for Q3 2023, and its period low was $9.5 million during Q3 2025.
  • Its 3-year average for Change in Acquisitions & Divestments is $24.1 million, with a median of $17.2 million in 2024.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Change in Acquisitions & Divestments tumbled by 7938.82% in 2024, and later plummeted by 1042.12% in 2025.
  • Orchestra BioMed Holdings' Change in Acquisitions & Divestments (Quarter) stood at $37.1 million in 2023, then crashed by 53.57% to $17.2 million in 2024, then plummeted by 44.81% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q3 2025, $16.4 million for Q2 2025, and $16.0 million during Q1 2025.